Author

J. M. Switchenko

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:Drosophila· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. C. Boese· 1 shared A. I. Marcus· 1 shared A. K. Nooka· 1 shared A. Moreno· 1 shared B. Wali· 1 shared C. Arciero· 1 shared C. C. Hofmeister· 1 shared C. Huang· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. C. Boese

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity

A. Moreno, K. Manning, M. I. Azeem, A. K. Nooka, M. Ellis, R. J. Manalo, J. M. Switchenko, B. Wali, J. L. Kaufman, C. C. Hofmeister, N. S. Joseph, S. Lonial, K. M. Dhodapkar, M. V. Dhodapkar, M. S. Suthar

This study examines how SARS-CoV-2 booster vaccines affect antibody profiles in myeloma patients, finding improved binding but not neutralization against variants.

bioRxiv · Aug 17, 2023 · PreprintImmunology

Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis.

C.-S. Seong, C. Huang, A. C. Boese, Y. Hou, J. Koo, J. K. Mouw, M. Rupji, G. Joseph, H. R. Johnston, H. Claussen, J. M. Switchenko, M. Behera, M. Churchman, J. M. Kolesar, S. M. Arnold, , M. Gilbert-Ross

The paper shows that loss of HD-PTP, a tumor suppressor, promotes RAS-driven oncogenesis and is associated with adenosquamous lung cancer, suggesting it as a therapeutic target.

bioRxiv · Jan 26, 2023 · PreprintCancer Biology